neo10qsb063004
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D. C. 20549
FORM 10-QSB
(X) Quarterly report pursuant to Section 13 or 15(d) of the Securities and
Exchange Act of 1934.
For the quarterly period ended June 30, 2004.
( ) Transition report pursuant to Section 13 or 15(d) of the Exchange Act for
the transition period from _____ ____________ to ____________ .
Commission File Number: 333-72097
NeoGenomics, Inc.
(Exact name of registrant as specified in charter)
Nevada 74-2897368
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
12701 Commonwealth Drive, Suite 9, Fort Myers, FL 33913
(Address of principal executive offices)
(239) 768-0600
(Registrant's Telephone Number, Including Area Code)
Check whether the registrant: (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements for the past
90 days.
YES (X) NO ( )
State the number of shares outstanding of each of the issuer's classes of common
equity, as of July 21, 2004.
19,849,416
Transitional Small Business Disclosure Format:
YES ( ) NO (X)
1
NeoGenomics, Inc.
INDEX TO FORM 10-QSB
PART I. FINANCIAL INFORMATION
Item 1. Consolidated Financial Statements (unaudited)
Consolidated Balance Sheet as of June 30, 2004..................... 4
Consolidated Statements of Operations for the three and six months
ended June 30, 2004 and 2003....................................... 5
Consolidated Statements of Cash Flows for the six months ended
June 30, 2004 and 2003............................................. 6
Notes to Consolidated Financial Statements......................... 7
Management's Discussion and Analysis of Financial Condition and
Item 2. Results of Operations (including cautionary statement)............. 11
Item 3. Controls and Procedures 15
PART II. OTHER INFORMATION
Item 1. Legal Proceedings.................................................. 16
Item 2. Changes in Securities.............................................. 16
Item 3. Defaults Upon Senior Securities.................................... 16
Item 4. Submission of Matters to a Vote of Securities Holders.............. 16
Item 5. Other Information.................................................. 16
Item 6. Exhibits and Reports on Form 8-K................................... 16
Signatures 17
2
PART I
FORWARD-LOOKING STATEMENTS
This Form 10-QSB, press releases and certain information provided
periodically in writing or orally by our officers or our agents contain
statements which constitute forward-looking statements within the meaning of
Section 27A of the Securities Act, as amended; Section 21E of the Securities
Exchange Act of 1934; and the Private Securities Litigation Reform Act of 1995.
The words "may", "would", "could", "will", "expect", "estimate", "anticipate",
"believe", "intend", "plan", "goal", and similar expressions and variations
thereof are intended to specifically identify forward-looking statements. These
statements appear in a number of places in this Form 10-QSB and include all
statements that are not statements of historical fact regarding the intent,
belief or current expectations of us, our directors or our officers, with
respect to, among other things: (i) our liquidity and capital resources; (ii)
our financing opportunities and plans; (iii) trends affecting our future
financial condition or results of operations; (iv) our growth strategy and
operating strategy; and (v) the declaration and payment of dividends.
Investors and prospective investors are cautioned that any such
forward-looking statements are not guarantees of future performance and involve
risks and uncertainties, and that actual results may differ materially from
those projected in the forward-looking statements as a result of various
factors. The factors that might cause such differences include, among others,
the following: (i) we have incurred significant losses since our inception, and
have experienced and continue to experience negative operating margins and
negative cash flows from operations (see Note B to the financial statements);
(ii) any material inability of us to successfully internally develop our
products; (iii) any adverse effect or limitations caused by Governmental
regulations; (iv) any adverse effect on our cash flow or on our ability to
obtain acceptable financing in connection with our growth plans; (v) any
increased competition in our business; (vi) any inability of us to successfully
conduct our business in new markets; and (vii) other risks including those
identified in our filings with the Securities and Exchange Commission. We
undertake no obligation to publicly update or revise the forward looking
statements made in this Form 10-QSB to reflect events or circumstances after the
date of this Form 10-QSB or to reflect the occurrence of unanticipated events.
3
NeoGenomics, Inc.
CONSOLIDATED BALANCE SHEET AS OF
June 30, 2004
(unaudited)
________________________________________________________________________________
ASSETS
CURRENT ASSETS:
Cash $ 190,880
Accounts receivable (net of allowance for
doubtful accounts of $6,234) 50,346
Inventories 9,635
Other current assets 2,831
Total current assets 253,692
PROPERTY AND EQUIPMENT (net of accumulated
depreciation of $125,641) 371,222
OTHER ASSETS - Deposits 2,221
TOTAL $ 627,135
============
LIABILITIES AND STOCKHOLDERS' DEFICIT
CURRENT LIABILITIES:
Accounts payable $ 27,205
Deferred revenue 110,000
Accrued and other liabilities 53,575
Due to affiliates 797,881
Total current liabilities 988,661
STOCKHOLDERS' DEFICIT:
Common stock, $.001 par value, 100,000,000 shares
authorized; 19,849,416 shares issued and
outstanding 19,849
Additional paid-in capital 9,161,231
Deficit (9,542,606)
Total stockholders' deficit (361,526)
TOTAL $ 627,135
============
________________________________________________________________________________
See notes to consolidated financial statements.
4
NeoGenomics, Inc.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
___________________________________________________________________________________________________
For the For the For the For the
Six-Months Six-Months Three-Months Three-Months
Ended Ended Ended Ended
June 30, 2004 June 30, 2003 June 30, 2004 June 30, 2003
REVENUE $ 300,396 $ 143,178 $ 121,533 $ 73,009
COST OF REVENUE 284,359 208,216 138,373 111,173
GROSS (DEFICIT) PROFIT 16,037 (65,038) (16,840) (38,164)
OPERATING EXPENSES:
Selling, general and administrative 310,420 175,341 128,650 91,678
Interest expense 43,969 13,223 23,253 8,954
Total operating expenses 354,389 188,564 151,903 100,632
NET INCOME (LOSS) $ (338,352) $ (253,602) $ (168,743) $ (138,796)
============= ============ =========== ===========
NET INCOME (LOSS) PER SHARE -
Basic and Diluted $ (0.02) $ (0.02) $ (0.01) $ (0.01)
============= ============ =========== ===========
WEIGHTED AVERAGE NUMBER
OF SHARES OUTSTANDING -
Basic and Diluted 18,625,680 10,253,236 18,801,943 15,960,702
============= ============ =========== ===========
___________________________________________________________________________________________________
See notes to consolidated financial statements.
5
NeoGenomics, Inc.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
___________________________________________________________________________________
For the For the
Six-Months Six-Months
Ended Ended
June 30, 2004 June 30, 2003
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss $(338,352) $(253,602)
Adjustments to reconcile net loss to net cash
provided by (used in) operating activities:
Depreciation 39,901 23,878
Provision for bad debts 9,041 9,596
Non-cash expenses - 20,925
Changes in assets and liabilities, net:
(Increase) decrease in accounts receivables,
net of write-offs 4,475 (38,028)
(Increase) decrease in inventory 957 (5,562)
(Increase) decrease in pre-paid expenses (1,099) (7,948)
(Increase) decrease in other current assets 894 2,000
(Increase) decrease in deposits 5,000 3,400
Increase (decrease) in due to bank - (13,518)
Increase (decrease) in deferred revenues - -
Increase (decrease) in accounts payable and
other liabilities (35,395) (58,335)
NET CASH (USED IN) PROVIDED BY OPERATING
ACTIVITIES (314,578) (317,194)
CASH FLOWS FROM INVESTING ACTIVITIES -
Purchases of property and equipment (13,437) (14,573)
CASH FLOWS FROM FINANCING ACTIVITIES:
Advances from affiliates, net 149,215 231,334
Issuances of common stock, net of transaction
expenses 344,629 114,271
NET CASH PROVIDED BY FINANCING ACTIVITIES 493,844 345,605
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 165,829 13,838
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 25,051 -
CASH AND CASH EQUIVALENTS, END OF PERIOD $ 190,880 $ 13,838
========== ==========
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid $ 52,651 $ 2,623
========== ==========
Income taxes paid $ - $ -
========== ==========
___________________________________________________________________________________
See notes to consolidated financial statements.
6
NeoGenomics, Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
________________________________________________________________________________
NOTE A - ORGANIZATION AND DESCRIPTION OF BUSINESS
NeoGenomics, Inc. ("NEO") was incorporated under the laws of the state of
Florida on June 1, 2001 and on November 14, 2001 agreed to be acquired by
American Communications Enterprises, Inc., a Nevada corporation ("ACE"). As a
result of the acquisition, NEO became the operating subsidiary of ACE. ACE was
formed in 1998 and succeeded to NEO's name on January 3, 2002 (collectively NEO
and ACE are referred to as "NeoGenomics", the "Company", "we", "us", or "our"
throughout this Form 10-QSB).
On April 4, 2003, we amended our articles of incorporation to (1) effect a
one-for-100 reverse split of our common stock, (2) reduce the authorized number
of common shares from 500,000,000 to 100,000,000, and (3) authorize 10,000,000
shares of preferred stock for future issuance, with such terms, restrictions and
limitations as may be established by the Board of Directors.
As a result of the above, all references to the number of shares and par value
in the accompanying consolidated financial statements and notes thereto have
been adjusted to reflect the April 2003 reverse stock split as though it had
been completed as of January 1, 2003.
Basis of Presentation
Our accompanying unaudited consolidated financial statements have been prepared
in accordance with accounting principles generally accepted in the United States
of America for interim financial information and the instructions to Form 10-QSB
and Rule 10-1 of Regulation S-X of the Securities and Exchange Commission (the
"SEC"). Accordingly, these consolidated financial statements do not include all
of the footnotes required by accounting principles generally accepted in the
United States of America. In our opinion, all adjustments (consisting of normal
and recurring adjustments) considered necessary for a fair presentation have
been included. Operating results for the six months ended June 30, 2004 are not
necessarily indicative of the results that may be expected for the year ended
December 31, 2004. The accompanying consolidated financial statements and the
notes thereto should be read in conjunction with our audited consolidated
financial statements as of and for the year ended December 31, 2003 contained in
our Form 10-KSB.
Principles of Consolidation
The accompanying consolidated financial statements include the accounts of NEO
and ACE. All significant intercompany accounts and balances have been eliminated
in consolidation.
Revenue Recognition
Net revenues are recognized in the period when tests are performed and consist
primarily of net patient revenues that are recorded based on established billing
rates less estimated discounts for contractual allowances principally for
patients covered by Medicare, Medicaid and managed care and other health plans.
These revenues also are subject to review and possible audit by the payers. We
believe that adequate provision has been made for any adjustments that may
result from final determination of amounts earned under all the above
arrangements. There are no known material claims, disputes or unsettled matters
7
with any payers that are not adequately provided for in the accompanying
consolidated financial statements.
Accounts Receivable and Allowance for Doubtful Accounts
We record accounts receivable net of estimated and contractual discounts. We
provide for accounts receivable that could become uncollectible in the future by
establishing an allowance to reduce the carrying value of such receivables to
their estimated net realizable value. We estimate this allowance based on the
aging of our accounts receivable and our historical collection experience for
each type of payer. Bad debts are charged off to the allowance account at the
time they are deemed uncollectible.
Use of Estimates
The preparation of financial statements in conformity with accounting principles
generally accepted in the United States of America requires us to make certain
estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of
the financial statements. The reported amounts of revenues and expenses during
the reporting period may be affected by the estimates and assumptions we are
required to make. Estimates that are critical to the accompanying consolidated
financial statements include estimates related to contractual adjustments, and
the allowance for doubtful accounts. It is at least reasonably possible that our
estimates could change in the near term with respect to these matters.
Reclassifications
Certain amounts in the 2003 financial statements have been reclassified to
conform with the 2004 presentation.
NOTE B - GOING CONCERN
Our consolidated financial statements were prepared using accounting principles
generally accepted in the United States of America applicable to a going
concern, which contemplates the realization of assets and liquidation of
liabilities in the normal course of business. We have incurred significant
losses since our inception, and have experienced and continue to experience
negative cash flows from operations. In addition, we expect to have ongoing
requirements for substantial additional capital investment to implement our
business plan. Since our inception, our operations have been funded through
private equity and debt, and we expect to continue to seek additional funding
through private or public equity and debt. As discussed in Note C, in connection
with this matter, in April 2003, we secured a commitment from a related entity
to provide us with $1.5 million of debt financing in the form of a revolving
credit facility. In addition, as discussed at Note D, during the period January
1, 2004 through July 20, 2004 we have raised approximately $500,000 from the
sale of our common stock, and we anticipate selling additional shares in the
future. Finally, we have begun to ramp up our laboratory operations and generate
operating revenues. However, there can be no assurance that cash generated from
operating and financing activities will be adequate to meet our needs. These
factors, among others, indicate that we may be unable to continue as a going
concern for a reasonable period of time.
Our consolidated financial statements do not include any adjustments relating to
the recoverability and classification of recorded asset amounts or the amounts
and classification of liabilities that might be necessary should we be unable to
continue as a going concern.
NOTE C - RELATED PARTY TRANSACTIONS
8
During 2003, we paid $72,500 to one of our Directors for various consulting work
in connection with helping to organize and manage our financial affairs. During
the six months ended June 30, 2004, we incurred and paid $32,000 to this same
Director for his continued services.
During 2002, we borrowed funds from the Naples Women's Center ("NWC"), a company
owned by our Chairman, to meet our short-term cash needs. These amounts were
advanced to us with a stated interest rate of 8% and are due in October of 2004.
At June 30, 2004, we owed NWC approximately $58,700.
In late 2002 and early 2003, in order to meet short term cash needs, we borrowed
$177,000 from three individuals who are affiliates of Medical Venture Partners,
LLC ("Medical Venture Partners"), a venture capital firm with whom we were
negotiating a financing transaction (see below). These amounts, having a stated
interest rate of 8%, were repaid in April 2003 in connection with the financing
transaction described below.
On April 15, 2003, we entered into debt and equity financing agreements with
Medical Venture Partners and its principals. Under the terms of the agreements,
affiliates of Medical Venture Partners purchased approximately 75% of our
outstanding common stock at that time and agreed to make available up to $1.5
million of debt financing in the form of a revolving credit facility (the
"Credit Facility"), with a stated interest rate of prime + 8%. The debt
financing and approximately 50.4% of the equity investment are being made
through MVP 3, LP, a fund controlled by Medical Venture Partners. The remainder
of the equity investment was made by the three principals of Medical Venture
Partners acting individually.
Under the terms of the Credit Facility, we are able to borrow up to $500,000 on
an unsecured basis, plus an amount not exceeding 80% of our "eligible" accounts
receivable (as defined) and 50% of our net furniture and equipment balance. At
June 30, 2004 we owed MVP 3, LP $739,215 under the Credit Facility and had
approximately $14,900 of due, but unpaid interest in our accounts payable
balance. Advances are secured by substantially all of the assets in the
accompanying consolidated balance sheet; however such security interest is
subordinate to the first security interest we granted to Fifth Third Bank, an
unrelated financial institution that has entered into a separate loan agreement
with MVP 3, LP and its principals. The Company is also a guarantor of certain
parts of this indebtedness with Fifth Third Bank. The Credit Facility matures on
March 31, 2005 and all amounts outstanding thereunder (including any unpaid
interest) are due at that time.
With respect to this agreement, we are subject to the following restrictive
covenants: (i) we are not to incur indebtedness outside of this agreement in
excess of $50,000 without written authorization of MVP 3, L.P., (ii) we cannot
declare or pay any dividend on our common stock, and (iii) we are also subject
to other general covenants typical of an instrument of this kind. In addition,
as a condition to these transactions, the Company, our President, MVP 3 LP and
the principals of Medical Venture Partners entered into a shareholders agreement
that provides that MVP 3, LP will have the right to appoint up to four of seven
of our directors. We also entered into a Registration Rights Agreement with MVP
3 LP and the principals of Medical Venture Partners granting them certain demand
and piggyback registration rights.
NOTE D - EQUITY FINANCING TRANSACTIONS
Between March 31, 2004 and June 30, 2004, we sold 1,400,000 shares of our common
stock in a series of private placements at $0.25/share to five unaffiliated
third party investors (see also Note E - Subsequent Events). These transactions
generated net proceeds to the Company of approximately $345,000 after deducting
for certain transaction expenses. Under the terms of the stock purchase
agreements used in these transactions, the Company has agreed to use its
reasonable best efforts to file with the SEC within 180 days of any transaction,
9
and to cause to be declared effective thereafter, a resale registration
statement which includes the shares purchased by such third party investors.
NOTE E - SUBSEQUENT EVENTS
Between July 1 and July 21, 2004, we sold 600,000 shares of our common stock in
a private placement at $0.25/share to unaffiliated third parties. These
transactions generated gross proceeds to the Company of $150,000. In addition,
we are in the process of closing equity transactions with a number of
unaffiliated third parties under the same terms as listed above.
NOTE F - BOARD OF DIRECTORS
On June 24, 2004, Mr. Kevin J. Lindheim resigned as a Director of the Company.
End of Financial Statements
10
Item 2. - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
Overview
NeoGenomics, Inc. operates a medical testing laboratory and research facility
based in Fort Myers, Florida that is targeting the rapidly growing genetic and
molecular testing segment of the medical laboratory market. Our common stock is
listed on the NASDAQ Bulletin Board (OTCBB) under the symbol "NGNM." Our
business plan features two concurrent objectives:
1. Development of a clinical laboratory to offer routine cytogenetics and
molecular biology testing services; and
2. Development of a research laboratory to offer sponsored research services to
other companies that are seeking to develop genomic products that will determine
the genetic basis for female and neonatal diseases, cancers and other forms of
disease (See "Research and Development").
The vision of NeoGenomics is to merge a high-end genetic and molecular testing
laboratory with ongoing research activities to help bridge the gap between
clinical medicine and genomic research. We believe that this combination will
allow the Company to speed the process of discovery and innovation and develop
new advanced testing methods to identify the genetic and molecular causes of
disease. Over the last 3-4 years, advances in technology and genetic research,
including the complete sequencing of the human genome, have made possible a
whole new set of tools to diagnose and treat diseases. This has opened up a vast
opportunity for laboratory companies that are positioned to address this growing
market segment.
The medical testing laboratory market can be broken down into three primary
segments:
o clinical lab testing,
o anatomic pathology testing, and
o genetic/molecular testing.
Clinical labs typically are engaged in high volume, high automation tests on
blood and urine. Clinical lab tests often involve testing of a less urgent
nature, for example, cholesterol testing and testing associated with routine
physical exams. This type of testing yields relatively low average revenue per
test. Anatomic pathology ("AP") testing involves evaluation of tissue, as in
surgical pathology, or cells as in cytopathology. AP testing typically seeks to
answer the question: is it cancer? The most widely known AP tests are Pap
smears, skin biopsies, and tissue biopsies. AP tests are typically more labor
and technology intensive than clinical lab tests and thus typically have higher
average revenue per test than clinical lab tests.
We believe genetic/molecular testing is the newest and fastest growing subset of
the laboratory market. Genetic testing or "cytogenetics" involves analyzing
chromosomes taken from the nucleus of cells for abnormalities in a process
called karyotyping. A karyotype evaluates the entire 46 human chromosomes by
number, and banding patterns to identify abnormalities associated with diseases.
Examples of cytogenetics testing include amniocentesis testing of pregnant women
to screen for genetic anomalies such as Down's syndrome in a fetus and bone
marrow testing to screen for types of leukemia. Molecular biology involves
testing for even more specific causes of diseases based on very small
alterations in cellular biology and DNA. Examples of common molecular biology
testing include screening for paternity, cystic fibrosis or Tay-Sachs disease.
11
Both cytogenetics and molecular biology have become important and accurate
diagnostic tools over the last five years and new tests are being developed
rapidly, thus this market segment is expanding rapidly. Genetic/molecular
testing requires very specialized equipment and credentialed individuals
(typically PhD level) to certify the results. As a result of the sophistication
involved in performing these tests, we believe that genetic/molecular testing
typically has the highest average revenue/test of the medical laboratory sub
segments.
Comparison of the Medical Testing Laboratory Market Segments:
Attributes Clinical Anatomic Pathology Genetic/Molecular
Testing Performed On Blood, Urine Tissue/cells Chromosomes/
molecules
Volume High Low Low
Physician Involvement Low High - Pathologist Low
Malpractice Insur. Required Low High Low
Other Professionals Req. None None Cyto Geneticist/
Molecular Geneticist
Level of Automation High None Moderate
Diagnostic in Nature Usually Not Yes Yes
Types of Diseases Tested Many Possible Primarily Cancer Rapidly Growing
Estimated Revenue/Test (1) $5 - $35/Test $25 - $400/Test $200 - $800/Test
Estimated Size of Market $25 - $30 Billion $6.0 - $7.0 Billion $1.0 - $2.0 Billion
Estimated Annual Growth Rate of 4.0 -5.0% 6.0 - 7.0% 25.0 - 40+%
Market 4.0 -5.0% 6.0 - 7.0% 25.0 - 40+%
Source: Research Analysts and Company Estimates
(1) Estimated Revenue/Test is for the technical component of such tests and does
not include revenue for the professional component or interpretation of such
tests.
We compete in the marketplace based on the quality and accuracy of our test
results, our turn-around times and our ability to provide after-test support to
those physicians requesting consultation. We believe our average three day
turn-around times on oncology-related cytogenetics tests is among the best in
the industry and is helping to increase the usage patterns of cytogenetics tests
by our referring oncologists and hematopathologists. Based on anecdotal
information, we believe that most competing cytogenetics labs typically have
7-21 day turn-around times on average. Traditionally, longer turn-around times
for cytogenetics tests have resulted in fewer tests being ordered since there is
an increased chance that the test results will not be returned within an
acceptable diagnostic window when other adjunctive diagnostic test results are
available. We believe our turn-around times are resulting in our referring
physicians requesting more of our testing services in order to augment or
confirm other diagnostic tests, thereby giving us a significant competitive
advantage in marketing our services against those of other competing
laboratories.
The cytogenetics and molecular biology testing markets in general are seasonal
and the volumes of such tests tend to decline somewhat in the summer months as
referring physicians and their patients are vacationing. In southern Florida,
currently our primary referral market for lab tests, this seasonality is further
exacerbated because a meaningful percentage of the population returns to homes
in the Northern U.S. to avoid the hot summer months. We estimate that our growth
rates during the second and third quarter of each year will be somewhat impacted
by these seasonality factors.
The following discussion and analysis should be read in conjunction with the
financial statements for the three and six months ended June 30, 2004, included
with this Form 10-QSB. Readers are also referred to the cautionary statement,
which addresses forward-looking statements made by us.
Critical Accounting Policies
12
Our critical accounting policies, including the assumptions and judgments
underlying them, are disclosed in the Notes to the Financial Statements for the
fiscal year ended December 31, 2003 included in our Form 10-KSB. We have
consistently applied these policies in all material respects. At this stage of
our development, these policies primarily address matters of revenue and expense
recognition. Management does not believe that our operations to date have
involved uncertainty of accounting treatment, subjective judgment, or estimates,
to any significant degree.
Results of Operations for the Three Months ended June 30, 2004 as Compared to
the Three Months ended June 30, 2003
During the three months ended June 30, 2004, we generated revenues and costs of
revenues of approximately $122,000 and $138,000, respectively, versus revenues
and costs of revenues of approximately $73,000 and $111,000, respectively for
the three months ended June 30, 2003. This resulted in a gross margin deficit of
approximately $17,000 for the three months ended June 30, 2004, which is a 55%
improvement over the gross margin deficit of $38,000 reported for the three
months ended June 30, 2003. This change is primarily attributable to our 67%
increase in revenues for the period ended June 30, 2004 as compared to the
period ended June 30, 2003. This increase was offset by additional costs
associated with moving to a new laboratory facility in August 2003 and costs of
additional laboratory personnel required to handle the substantial increase in
testing volumes versus the prior period. We believe our gross margin will
continue to improve as we perform more tests. During the most recent quarter, we
further increased our penetration into existing referral sources for cytogentics
tests and added a number of new referral sources, which helped to offset the
historical reduction in testing volumes attributable to seasonality issues
associated with our geographic market.
Our selling, general and administrative expenses for the most recent quarter
were approximately $129,000, versus selling, general and administrative expenses
of approximately $92,000 for the three months ended June 30, 2003. This increase
was primarily due to an increase in headcount to support the growth of our
operations. Interest expense for the most recent quarter was approximately
$23,000, compared to approximately $9,000 of interest reported for the three
months ended June 30, 2003. Interest expense is primarily comprised of interest
payable on advances under our Credit Facility as well as interest payable on
advances from other related parties and the increase is primarily a result of
our increased borrowing.
Results of Operations for the Six Months ended June 30, 2004 as Compared to the
Six Months ended June 30, 2003
During the six months ended June 30, 2004, we generated revenues and costs of
revenues of approximately $300,000 and $284,000, respectively, versus revenues
and costs of revenues of approximately $143,000 and $208,000, respectively, for
the six months ended June 30, 2003. This resulted in a positive gross margin of
approximately $16,000 for the six months ended June 30, 2004, which is an
approximately $82,000 improvement over the gross margin deficit of approximately
$65,000 reported for the six months ended June 30, 2003. This change is
primarily attributable to our 110% increase in revenues for the period ended
June 30, 2004 as compared to the period ended June 30, 2003. This increase was
offset by additional costs associated with moving to a new laboratory facility
in August 2003 and costs of additional laboratory personnel required to handle
the substantial increase in testing volumes versus the prior period.
Our selling, general and administrative expenses for the six months ended June
30, 2004 were approximately $310,000, versus selling, general and administrative
expenses of approximately $175,000 for the six months ended June 30, 2003. This
increase was primarily due to an increase in sales and management headcount to
support the growth of our operations. Interest expense for the six months ended
June 30, 2004 was approximately $44,000, compared to approximately $13,000 of
interest reported for the six months ended June 30, 2004. Interest expense is
13
primarily comprised of interest payable on advances under our Credit Facility as
well as interest payable on advances from other related parties and the increase
is primarily a result of our increased borrowing.
Liquidity and Capital Resources
During the six months ended June 30, 2004, our operating activities used
approximately $315,000 in cash. This amount primarily represented cash used to
pay general and administrative expenses associated with our operations and fund
our working capital needs. We also spent approximately $13,000 on new equipment.
We were able to finance operations and equipment purchases primarily through the
sale of equity securities and net advances under our Credit Facility, which
together provided approximately $494,000 over the six months ended June 30,
2004. At June 30, 2004, we had cash and cash equivalents of approximately
$191,000.
On April 15, 2003, we entered into equity and debt financing agreements with
Medical Venture Partners and its principals. Under the terms of the equity
agreements, affiliates of Medical Venture Partners purchased 13,927,062 shares
of our common stock for $0.01 per share which resulted in net proceeds to the
company of $114,271 after deducting transaction expenses of approximately
$25,000. As a result of these equity transactions, the Company experienced a
change of control. Under the terms of the debt financing agreements, MVP 3, LP,
a partnership controlled by Medical Venture Partners, agreed to make available
up to $1.5 million of debt financing in the form of a revolving credit facility
(the "Credit Facility").
Under the terms of the Credit Facility, our advances are limited, at any given
time, to the sum of i) 50% of our net property, plant and equipment; (ii) 80% of
our accounts receivable that are less than 90 days old; and (iii) $500,000 that
is not tied to any specific collateral. Interest under the revolving credit
agreement is payable monthly at the prime rate plus 8.0%. As of June 30, 2004,
we had approximately $739,000 in principal amount outstanding under the Credit
Facility.
Over the next twelve months, we plan to finance our operations through cash on
hand, sales of equity securities and borrowings under the Credit Facility with
MVP 3. While we believe that, based on our current business plan, these sources
will be sufficient to finance our operations over the next twelve months, there
can be no assurance that we will have sufficient cash on hand or be able to
realize a sufficient amount of capital from the sale of equity securities or
have sufficient availability under our Credit Facility to fund our operations.
If we are unable to obtain such funding, we will be required to curtail or
discontinue operations.
Capital Expenditures
We currently forecast capital expenditures for the coming year in order to
execute on our business plan. We plan to fund these expenditures through
borrowings under our Credit Facility with MVP 3, LP and through traditional
lease financing from equipment lessors. There can be no assurance that we will
be eligible to obtain all of our capital equipment funding needs from MVP 3, LP
or another source. If we are unable to obtain such funding, we will be required
to curtail our equipment purchases, which may have an impact on our ability to
generate revenues.
Staffing
We plan to increase our work force. Currently, we have six full-time and two
part-time employees. We plan to add additional laboratory technicians and
research scientists to assist us in handling a greater volume of tests and to
14
perform sponsored research projects. In addition, we intend to continue building
our sales force in an effort to sustain our sales growth, as well as add
personnel in management, accounting, and administrative functions.
Item 3 - CONTROLS AND PROCEDURES
We maintain disclosure controls and procedures designed to ensure that
information required to be disclosed in reports filed under the Securities
Exchange Act of 1934, as amended, is recorded, processed, summarized and
reported within the specified time periods. As of the end of the period covered
by this report, our Chief Executive and Principle Financial Officer evaluated
the effectiveness of our disclosure controls and procedures. Based on the
evaluation, which disclosed no significant deficiencies or material weaknesses,
our Chief Executive and Principle Financial Officer concluded that our
disclosure controls and procedures are effective as of the end of the period
covered by this report. There were no changes in our internal control over
financial reporting that occurred during the most recent fiscal quarter that
have materially affected, or are reasonably likely to materially affect, our
internal control over financial reporting.
15
PART II. - OTHER INFORMATION
Item 1. Legal Proceedings
NONE
Item 2. Changes in Securities
Between March 31 and June 30, 2004, we sold 1,400,000 shares of our common stock
at $0.25/share, which generated net proceeds to the Company, after deducting
certain transaction expenses, of approximately $345,000. These shares are
initially restricted shares, however, the Company has agreed to use its
reasonable best efforts to file with the SEC within 180 days after any
transaction, and cause to become effective thereafter, a resale registration
statement covering such shares.
Item 3. Defaults Upon Senior Securities
NONE
Item 4. Submission of Matters to a Vote of Securities Holders
NONE
Item 5. Other Information
NONE
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits
The following exhibits are filed as part of this Form 10-QSB.
Exhibit
Number Description
31.1 Certification of NeoGenomics, Inc. Chief Executive and
Principal Financial Officer, Thomas H. White, pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 Certification of NeoGenomics, Inc. Chief Executive and
Principal Financial Officer, Thomas H. White, pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002.
(b) Reports on Form 8-K.
No reports on Form 8-K were filed with the SEC during the period covered by
this report.
16
SIGNATURES
In accordance with Section 13 or 15(d) of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
NEOGENOMICS, INC.
Date: July 21, 2004 /s/ Thomas H. White
Thomas H. White
Chief Executive and
Principal Financial Officer
17